The role of monoclonal antibody affinity in tumor immunotherapy evaluated in in vivo models for minimal residual disease

Journal of Immunotherapy

Volumn 19, Issue 4, 1996, Pages 245-256

  Velders, Markwin P ^a   Van Rhijn, Connie M ^a   Cornelissen, Ine M H A ^b   Van Muijen, Goos N P ^b   Briaire, Inge H ^a   Dohlsten, Mikael ^c   Fleuren, Gert Jan ^a   Warnaar, Sven O ^a   Litvinov, Sergey V ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Affinity; Monoclonal antibody; Murine models; NK cells

Indexed keywords

CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; LUNG METASTASIS; MELANOMA CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 0029787797     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199607000-00001     Document Type: Article

References (24)

1. Johansson C, Segren S, Lindholm L. Tumour-growth suppression in nude mice by a murine monoclonal antibody: factors hampering successful therapy. Int J Cancer 1991;48:297-304.
2. Velders MP, van Rhijn CM, Briaire IH, Fleuren GJ, Warnaar SO, Litvinov SV. Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model. Cancer Res 1995;55:4398-403.
3. Riethmüller G, Schneider-Gadicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994;343:1177-83.
4. Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon cancer. N Engl J Med 1990;322:352-8.
5. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15.
6. Velders MP, Litvinov SV, Warnaar SO, et al. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 1994;54:1753-9.
7. Dohlsten M, Abrahmsen L, Bjork P, et al. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci USA 1994;91:8945-9.
8. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979;76:1438-52.
9. Edwards DP, Grzyb KT, Dressler LG, et al. Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res 1986;46:1306-17.
10. Litvinov SV, Velders MP, Bakker HAM, Fleuren GJ, Warnaar SO. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994;125:437-46.
11. Linnenbach AJ, Seng BA, Wu S, et al. Retropositon in a family of carcinoma-associated antigen genes. Mol Cell Biol 1993;13:1507-15.
12. Pak KY, Nedleman MA, Fogler WE, et al. Evaluation of the 323/A3 monoclonal antibody and the use of technetium-99m-labeled 323/A3 Fab′ for the detection of pan adenocarcinoma. Int J Rad Appl Instrum 1991;18:483-97.
13. 125I-antibody therapy efficacy in multicell spheroids. Cancer Res 1992;52:4728-34.
14. Herlyn D, Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci USA 1982;79:4761-5.
15. Kumar S, Vinci JM, Pytel BA, Baglioni C. Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res 1993;53:348-53.
16. Cheung NKV, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinsky ML, Medof ME. Decay-accelerating factor protects human tumor cells from complement mediated cytotoxicity in vitro. J Clin Invest 1988;81:1122.
17. Eisenthal A, Rosenberg SA. Systemic induction of cells mediating antibody-dependent cellular cytotoxicity following administration of interleukin 2. Cancer Res 1989;49:6953-9.
18. Holub M. Immunology of nude mice. Boca Raton, Florida: CRC Press, Inc., 1989.
19. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. Int J Cancer 1975;16:216.
20. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse I: Cytotoxic cells with specificity for mouse Moloney leukemia cells: specificity and distribution according to genotype. Eur J Immunol 1975;5:112.
21. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986;319:675-8.
22. Ciccone E, Pende D, Viale O, et al. Specific recognition of human CD3-CD16+ natural killer cells requires the expression of an autosomic recessive gene on target cells. J Exp Med 1990;172:47-52.
23. Correa I, Corral L, Raulet DH. Multiple natural killer cell-activating signals are inhibited by major histocompatibility complex class I expression in target cells. Eur J Immunol 1994;24:1323-31.
24. Eisenthal A, Cameron RB, Rosenberg SA. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. J Immunol 1990;144:4463-71.